Univercells Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 143
Employees
  • Latest Deal Type
  • Debt
  • Latest Deal Amount
  • $36.1M
Latest Deal Amount
  • Investors
  • 17

Univercells General Information

Description

Developer of vaccines and bio-therapeutics intended to address global health challenges. The company delivers novel biomanufacturing platforms and solutions aiming at making biologics available and affordable to all by relying on proprietary core technologies and a continuous process intensification approach, production is achieved with a smaller footprint, and significantly lower overall capital and operational costs, enabling clients to deliver novel technologies and solutions breaking the barriers to bioproduction.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • Rue Auguste Piccard 48
  • Gosselies
  • 6041 Gosselies
  • Belgium
+32 02 000 00 00

Univercells Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Univercells Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Debt - General 01-Jul-2021 $36.1M 00000 Completed Generating Revenue/Not Profitable
9. Later Stage VC (Series C) 17-Dec-2020 000.00 00000 00000 Completed Generating Revenue/Not Profitable
8. Later Stage VC 01-Mar-2020 000.00 000.00 00000 Completed Generating Revenue/Not Profitable
7. Debt - General 03-Oct-2019 0000 000.00 Completed Generating Revenue/Not Profitable
6. Early Stage VC (Series B) 16-Jul-2018 000.00 000.00 000.00 Completed Generating Revenue/Not Profitable
5. Grant 23-Jan-2018 00.00 00.000 Completed Startup
4. Early Stage VC (Series A2) 15-Dec-2017 00.000 00.000 000.00 Completed Startup
3. Grant 15-Dec-2016 000.00 00.000 Completed Startup
2. Early Stage VC (Series A) 18-Jul-2016 $3.33M $3.33M 000.00 Completed Startup
1. Accelerator/Incubator 01-Oct-2014 Completed Startup
To view Univercells’s complete valuation and funding history, request access »

Univercells Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class C 000,000 000.00 000.00 00 000.00 00.000
Class G 000,000 000.00 000.00 00 000.00 0.000
Class B 000,000 000.00 000.00 00 000.00 00.00
Convertible 37,773 $24.03 $24.03 1x $24.03 1.94%
Class A 304,196 $24.03 $24.03 1x $24.03 15.6%
To view Univercells’s complete cap table history, request access »

Univercells Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of vaccines and bio-therapeutics intended to address global health challenges. The company delivers novel biom
Biotechnology
Gosselies, Belgium
143 As of 2021
00000
000000000 00000

00000000

la pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt moll
0000000000000
Reykjavík, Iceland
000 As of 0000
00000
000000000 00000

000000 0

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
Chengdu, China
000 As of 0000
00000
0.000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Univercells Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alvotech Private Equity-Backed Reykjavík, Iceland 000 00000 000000000 00000
000000 00000000000 Formerly VC-backed Chengdu, China 000 00000 00000000 00000
0000000000 Venture Capital-Backed Frederick, MD 00 00.000 0000000000 00.000
000000000 Venture Capital-Backed Berlin, Germany 00 00000 0000000000 0 00000
0000000 Formerly VC-backed Fremont, CA 00 000.00 000000&0 000.00
You’re viewing 5 of 17 competitors. Get the full list »

Univercells Patents

Univercells Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3867352-A1 Method for decontaminating a biomolecule production system and a system suitable for decontamination Pending 19-Oct-2018 000000000
AU-2019309101-A1 System and method for the production of biomolecules Pending 27-Jul-2018 000000000
EP-3830235-A1 System and method for the production of biomolecules Pending 27-Jul-2018 000000000
CA-3106661-A1 System and method for the production of biomolecules Pending 27-Jul-2018 000000000
US-20210155892-A1 System and method for the production of biomolecules Pending 27-Jul-2018 C12M47/10

Univercells Executive Team (12)

Name Title Board Seat Contact Info
Mathias Garny Chief Executive Officer
Vincent Vanderborght Chief Financial Officer
David Louvet Chief Human Resources Officer & Chief Operating Officer
Christian Borgniet Chief Operating Officer
José Castillo Ph.D Co-Founder, Chief Technical Officer & Board Member
You’re viewing 5 of 12 executive team members. Get the full list »

Univercells Board Members (12)

Name Representing Role Since
Andre Ostachkov Univercells Board Observer 000 0000
Doug Neugold Self Chairman 000 0000
Glenn Rockman Global Health Investment Fund Board Member 000 0000
Jean-Marc Legrand TheClubDeal Board Observer 000 0000
José Castillo Ph.D Univercells Co-Founder, Chief Technical Officer & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Univercells Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Univercells Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adjuvant Capital Impact Investing Minority 000 0000 000000 0
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
Federal Holding and Investment Company Holding Company Minority 000 0000 000000 0
Gamma Biosciences PE-Backed Company Minority 000 0000 000000 0
Health Technology Holding Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Univercells Subsidiaries (1)

Company Name Industry Location Founded
00000000 BPO/Outsource Services Jumet, Belgium 0000
To view Univercells’s complete subsidiaries history, request access »